ATE539763T1 - Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit - Google Patents

Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit

Info

Publication number
ATE539763T1
ATE539763T1 AT06780613T AT06780613T ATE539763T1 AT E539763 T1 ATE539763 T1 AT E539763T1 AT 06780613 T AT06780613 T AT 06780613T AT 06780613 T AT06780613 T AT 06780613T AT E539763 T1 ATE539763 T1 AT E539763T1
Authority
AT
Austria
Prior art keywords
disease
parkinson
alzheimer
growth factor
nervous system
Prior art date
Application number
AT06780613T
Other languages
English (en)
Inventor
Alessandro Lambiase
Stefano Bonini
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Application granted granted Critical
Publication of ATE539763T1 publication Critical patent/ATE539763T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06780613T 2005-08-19 2006-08-11 Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit ATE539763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
PCT/IT2006/000620 WO2007020672A2 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease

Publications (1)

Publication Number Publication Date
ATE539763T1 true ATE539763T1 (de) 2012-01-15

Family

ID=37667295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06780613T ATE539763T1 (de) 2005-08-19 2006-08-11 Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit

Country Status (11)

Country Link
US (1) US20090118177A1 (de)
EP (1) EP1948217B1 (de)
JP (1) JP2009504724A (de)
AT (1) ATE539763T1 (de)
CA (1) CA2619721A1 (de)
DK (1) DK1948217T3 (de)
ES (1) ES2376992T3 (de)
IL (1) IL189605A (de)
IT (1) ITRM20050447A1 (de)
RU (1) RU2429007C2 (de)
WO (1) WO2007020672A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2173344T3 (en) * 2007-06-29 2016-07-25 Clarencew Pty Ltd TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEURO PSYCHIATRIC DISORDERS USING ocular administration
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神（北京）生物制药股份有限公司 一种眼用原位凝胶
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959319A (en) * 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
WO2000007613A1 (en) * 1998-08-05 2000-02-17 Advanced Medicine Research Institute Remedies for cerebral central lesions with the use of neurotrophic factors
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) * 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
RU2251429C2 (ru) * 2002-12-30 2005-05-10 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Фармацевтическая композиция для лечения ишемического инсульта и способ лечения

Also Published As

Publication number Publication date
RU2008110505A (ru) 2009-09-27
RU2429007C2 (ru) 2011-09-20
DK1948217T3 (da) 2012-02-20
JP2009504724A (ja) 2009-02-05
IL189605A (en) 2013-10-31
CA2619721A1 (en) 2007-02-22
IL189605A0 (en) 2008-06-05
EP1948217A2 (de) 2008-07-30
WO2007020672A2 (en) 2007-02-22
WO2007020672A3 (en) 2007-05-31
ES2376992T3 (es) 2012-03-21
ITRM20050447A1 (it) 2007-02-20
US20090118177A1 (en) 2009-05-07
EP1948217B1 (de) 2012-01-04

Similar Documents

Publication Publication Date Title
Su et al. Enhancing brain plasticity to promote stroke recovery
Koshimori et al. Future perspectives on neural mechanisms underlying rhythm and music based neurorehabilitation in Parkinson’s disease
Fisher et al. AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease
Zhou et al. Current evidence, clinical applications, and future directions of transcranial magnetic stimulation as a treatment for ischemic stroke
Wang et al. Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells
Nam et al. Acupuncture stimulation induces neurogenesis in adult brain
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
BR112015020391A2 (pt) gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina
Wei et al. Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway
Billeri et al. A narrative review on non-invasive stimulation of the cerebellum in neurological diseases
Guo et al. Use of transcutaneous auricular vagus nerve stimulation as an adjuvant therapy for the depressive symptoms of COVID-19: A literature review
Gao et al. Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease
IL189605A0 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
Cavalli et al. Role of acupuncture in the management of severe acquired brain injuries (sABIs)
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
Calne Parkinsonism: Clinical and neuropharmacologic aspects
Georgescu Margarint et al. Reduced interhemispheric coherence in cerebellar kainic acid-induced lateralized dystonia
Doshi et al. Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts
Huang et al. 2017 yearbook of neurorestoratology
Gao et al. Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Poniatowski et al. Dose-ranging effects of the intracerebral administration of atsttrin in experimental model of Parkinson’s disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice
Bernert et al. Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome
Lee et al. The Fundamental Mechanism of Transcranial Electrical Stimulation in Post-Stroke Rehabilitation
Jiao Embryonic and adult neural stem cell research in China
WO2014068171A1 (en) N-substituted 4-aminophenols and corresponding quinone imines